By Ellen Beck
UPI
Published 4/29/2002
WASHINGTON, April 29 (UPI) -- Congress has returned to the Medicare
prescription drug coverage debate after a hiatus since Sept. 11, but even
as Republicans and Democrats work to close a $100 billion gap in proposed
spending plans each day of delay is politically risky.
The risk is at best losing out to a niche bill covering less than the
comprehensive umbrella Medicare prescription drug benefit both parties
espouse. The worst-case scenario is losing out entirely, passing nothing
while the marketplace and the states do a drug coverage end-run around
Capitol Hill, creating embarrassment for lawmakers who then would be viewed
as not fulfilling promises because of partisan bickering.
Either way, seniors end up with the short end of the stick, a worry
to senior groups carefully watching the Hill this spring.
"It would be just be a shame and a betrayal of promises if we miss
the opportunity to cover all Medicare beneficiaries," said Rep. Janice
Schakowsky, D-Ill.
There is an analogy to be made with the much-debated Patients' Bill
of Rights, still not passed, which was proposed by President Clinton in
1996 and first introduced as legislation in 1997. Both sides agreed it
was must-pass legislation -- several years in a row -- but the key dividing
issue was and remains a patient's right to sue a health plan.
As the argument drones on, some states have considered legislation
allowing patient suits in state courts while other key parts of the legislation
are being addressed by an industry cognizant of consumer criticism and
demand.
Many insurance plans now allow women open access to a gynecologist,
it is rare anymore to hear about so-called drive-thru mastectomies, access
to emergency care has been opened up and most strict gatekeeper rules that
prevented patients from seeing specialists have been relaxed or removed.
Problems still exist in access to and quality of health care that comprehensive
legislation might have addressed, but the industry has moved a long way
toward answering the public's criticism of managed care, in the process
making Congress appear ineffective.
The Medicare prescription drug debate is similar. While lawmakers have
argued the appropriate generosity of such a benefit -- including coverage
limits and deductibles -- states have worked through Medicaid programs
and other agencies to provide help to low-income seniors who cannot afford
prescription drugs. Pharmaceutical companies offer drug discount plans
rivaling and in some cases even more generous than the one proposed by
the Bush administration.
Within the next month, the Senate Finance Committee also is expected
to take up a bill that could further fracture the comprehensive drug benefit
movement. It would require Medicare to cover only oral cancer drugs. Medicare
already covers cancer drugs given by intravenously or by injection in a
physician's office but not the powerful oral medications, such as Gleevec.
Representatives from both political parties and senior groups told
United Press International they still want a comprehensive Medicare drug
benefit and Medicare reform, so there is a waiting and watching game afoot
on Capitol Hill. Few are willing to predict what will happen by fall. If
the Patients Bill of Rights is any example, however, nothing will happen
and lawmakers will head into fall campaigning with little to show for the
rhetoric.
The GOP-controlled House says it will have a comprehensive bill voted
out by Memorial Day; the Democratic-controlled Senate is looking longer
into the summer. There are numerous spending proposals, but House Republicans
have proposed around $350 billion over 10 years while Senate Democrats
want $450 billion to $500 billion.
The question, say Republicans, is how to persuade the Democrats to
move closer to their side -- allowing higher deductibles and lower spending
caps and more restrictions. There is talk the GOP may move to offer some
type of 80/20 plan in which Medicare would pay 80 percent of prescription
costs, Schakowsky told UPI.
"Then we'd take the funding from within Medicare, reducing payments
to hospitals and adding a co-pay for home care -- just cannibalizing the
Medicare program itself," she said.
Democrats stand firm on getting the full Medicare proposal through
and the Senate Democratic caucus is ready to work up its own proposal.
"It's a top priority for Democrats," a Democratic staffer told UPI.
Some expect the GOP-controlled House to approve a Republican proposal
down party lines, which then will run into stiff opposition when Senate
Democrats come up with what may be a negotiating key. Or, just as likely,
nothing may happen.
The office of Sen. Olympia Snow, R-Maine, who introduced the "Access
to Cancer Therapies Act," is optimistic the bill will pass -- it is just
a question of how. If there is no chance for a comprehensive Medicare bill,
then there apparently is enough bipartisan support to pass Snow's bill
on its own. If the comprehensive format makes it through this session,
it is a moot point.
A representative of a major senior group, however, told UPI the idea
that passing something in Medicare drug coverage is better than nothing
is not necessarily true and the goal still is a full prescription drug
benefit.
Bills like Snow's cancer drug proposal put such groups in an awkward
position with their constituency. "It doesn't propose a solution ... it
perpetuates the problem," the representative said, noting it is very difficult
to tell a senior with a heart condition who cannot afford prescription
medication he or she is "not lucky enough to have cancer."
Schakowsky has not ruled out a comprehensive Medicare drug benefit.
"We can do anything we want to this year and that is a point that has to
be made to the public. We could have it, if it were viewed as a priority.
There is no question in my mind," she said.
|